Low Expression of Mir-155 in Vincristine Resistant Diffuse Large B-Cell Lymphoma

Hanne Due(Aalborg University Hospital), Karen Dybkær(Aalborg University Hospital), Anna A. Schönherz(Aalborg University Hospital), Alexander Schmitz(Chr. Hansen (Denmark)), Hans Erik Johnsen(Herlev Hospital), Julie Støve Bødker(Chr. Hansen (Denmark)), Louise Bechmann Krogh(Aarhus University), Martin Bøgsted(Chr. Hansen (Denmark)), Rasmus Froberg Brøndum(Aarhus University), Jacob Giehm Mikkelsen(Aarhus University), Anne Stidsholt Roug(Aalborg University Hospital)

VBN Forskningsportal (Aalborg Universitet)

January 1, 2016

Cited by 1

Related Papers

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

|Blood|2013|683

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

|Blood|2012|396

Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma

|Blood|2009|390

Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

|Leukemia|2012|362

IFI16 senses DNA forms of the lentiviral replication cycle and controls HIV-1 replication

|Proceedings of the National Academy of Sciences|2013|342